SynthesisFrontiers in oncology2026
Efficacy and cosmetic outcomes of radiotherapy modalities in early-stage breast cancer: a systematic review and network meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is a common malignancy with increasing annual incidence. Radiotherapy shows favorable clinical efficacy in BC management, but limited randomized controlled trial data is a major limitation. Therefore, further validation of the optimal radiotherapeutic strategy for early-stage BC is required. This network meta-analysis evaluated radiotherapy regimens' effects on efficacy and cosmetic outcomes in early-stage BC, guiding clinical practice. A comprehensive literature search was conducted in PubMed, Cochrane Library, Embase, and Web of Science databases to identify randomized controlled trials and cohort studies investigating radiotherapy approaches for early-stage BC. Data screening and extraction were independently performed using a standardized protocol. Study quality was assessed using the Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. The primary endpoint was ipsilateral breast recurrence (IBR), and secondary endpoints included locoregional recurrence, overall survival, disease-free survival, and cosmetic outcomes. Statistical analyses were performed using R 4.4.1 and STATA 18.0. A total of 36 studies involving 32,655 patients and 9 interventions were included. The lowest IBR rate was observed in patients treated with hypofractionated whole-breast irradiation (HF-WBI) (surface under the cumulative ranking curve [SUCRA], 10.54%), followed by conventional fractionated whole-breast irradiation (CF-WBI) (SUCRA, 35.70%). Compared with CF-WBI, intraoperative electron radiotherapy (IOeRT) (odds ratio [OR], 4.19; 95% credible interval [CrI], 1.83-10.26), intraoperative radiotherapy (IORT) (OR, 1.75; 95% CrI, 1.06-2.87), and HF-WBI (OR, 0.78; 95% CrI, 0.56-0.99) demonstrated statistically significant differences. The best cosmetic outcomes were achieved with three-dimensional conformal radiotherapy (3D-CRT) (SUCRA, 14.43%), followed by intensity-modulated radiotherapy (IMRT) (SUCRA, 16.04%). Compared with CF-WBI, 3D-CRT (OR, 0.11; 95% CrI, 0.01-0.85), IMRT (OR, 0.13; 95% CrI, 0.01-0.72), and IOeRT (OR, 0.25; 95% CrI, 0.04-0.78) showed statistically significant improvements. Since evidence supporting cosmetic outcomes is limited, findings should be interpreted with caution. Among patients with early-stage BC, HF-WBI was associated with the lowest rate of postoperative ipsilateral recurrence, whereas CF-WBI was associated with the second-lowest rate. In terms of cosmetic outcomes, 3D-CRT and IMRT demonstrated favorable clinical efficacy. Additional randomized controlled trials are necessary to clarify the comparative advantages and limitations of CF-WBI, HF-WBI, 3D-CRT, and IMRT, thereby strengthening the evidence base for early-stage BC radiotherapy strategies. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251173161.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.